First multicenter study of modified release phosphatidylcholine “LT-02” in ulcerative colitis: a randomized, placebo-controlled trial in mesalazine-refractory courses
This 2014 multicenter, double-blind, randomized, placebo-controlled trial evaluated the efficacy and safety of LT-02, a modified-release phosphatidylcholine formulation, in patients with mesalazine-refractory ulcerative colitis. Conducted across 24 centers in Germany, Lithuania, and Romania, 156 patients were assigned to receive placebo or LT-02 at doses of 0.8, 1.6, or 3.2 g/day
June 26, 2025
No Comments